As reported in Table 1, ROC analysis for CDH17 (GC stages II-III), performed to differentiate between GC stages and controls, gave an AUC of 0.667 (p = 0.003), with a sensitivity of 77.3% and specificity of 61.4%, and ROC analysis for TFF3 (GC stage I) gave a higher AUC of 0.703 (p = 0.001), with a sensitivity of 83.3% and specificity of 54.5% [55]. This evidence concerns the gene TFF3 and gastric cancer.